Glaukos is transforming the treatment of chronic eye diseases with novel therapies that provide sustainable solutions to important clinical needs.
Founded in 1998, Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases.
We were the first company to bring to market Micro-Invasive Glaucoma Surgery (MIGS), the micro-invasive procedure that revolutionised the treatment and management of glaucoma. In 2012, we launched our first MIGS device—the iStent®—in the United States, followed by our next-generation iStent inject® device in September 2018 and iStent inject® W in September 2020.
In November 2019, Glaukos acquired Avedro, maker of the first and only FDA-approved cross-linking technology for progressive keratoconus. And we continue to seek to leverage our platform technologies to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies for glaucoma, corneal health, and retinal diseases.
Our company completed an initial public offering in June of 2015, and our shares are traded on the New York Stock Exchange under the ticker symbol “GKOS”. Our global headquarters is located in San Clemente, California, and we have additional locations in 9 regions around the world.
At Glaukos, we are dedicated to addressing the greatest unmet needs of the global ophthalmic market, for physicians and for patients. That’s why we’ve spent more than a decade re-investing in R&D and clinical trial programs to develop and advance a deep pipeline of novel therapies currently being evaluated in FDA clinical trials, while leading the industry in clinical support and patient education resources. And it’s why we’re seeking to leverage our platform technologies to build an unrivaled portfolio of next-generation surgical and pharmaceutical therapies in glaucoma, corneal health, and retinal disease.
We’ve achieved many firsts in clinical studies and over the past several years, Glaukos has reinvested approximately 30% of all sales back into research and development activities – all to relentlessly advance our goal of creating and delivering transformative therapies for patients struggling with eye diseases and the skilled surgeons dedicated to their healing.
We’re proud of the corporate citizenship efforts of the Glaukos Charitable Foundation, Company and employees, and pledge to continue this important work in helping improve the lives of those suffering and in need.